老年人抗体相关中枢神经系统综合征可无炎症表现
该回顾性分析纳入155例≥60岁、存在抗神经元表面抗体相关神经综合征的患者,其中35例(22.6%)脑MRI无炎症异常且脑脊液无细胞增多。这35例中位年龄68岁,表现为面臂肌张力障碍性发作(均LGI1抗体)、IgLON5抗体相关步态不稳/脑干功能障碍/睡眠障碍、自身免疫性脑炎样表现及快速进展性认知衰退。结论提示即使MRI和脑脊液无炎症证据,识别特征性综合征也应促使抗体检测。
要点
- ≥60岁抗体相关中枢神经综合征患者中22.6%无MRI炎症及脑脊液细胞增多。
- 面臂肌张力障碍性发作均与LGI1抗体相关,应警惕并检测抗体。
- IgLON5抗体相关步态不稳、脑干功能障碍和睡眠障碍是特征性表现。
核心结论
- ≥60岁患者即使脑MRI和脑脊液无炎症证据,识别特征性中枢神经综合征也应进行抗体检测。
- 约15%的患者出现快速进展性认知衰退,增加了与神经退行性疾病的鉴别难度。
研究设计与样本
- 回顾性临床分析,纳入155例≥60岁、抗神经元表面抗体相关神经综合征患者。
- 入组标准:年龄≥60岁、脑MRI无炎症异常、脑脊液无细胞增多。
主要发现
- 35例(22.6%)符合无炎症标准,中位年龄68岁(范围60-88岁)。
- 面臂肌张力障碍性发作见于11/35(31.4%),均为LGI1抗体。
- IgLON5抗体相关步态不稳、脑干功能障碍和睡眠障碍见于10例(28.6%)。
- 自身免疫性脑炎样表现(急性意识模糊、记忆丧失、行为改变)见于9例(25.7%)。
- 快速进展性认知衰退见于5例(14.3%)。
临床怎么用
- 对≥60岁出现面臂肌张力障碍性发作、IgLON5抗体综合征或自身免疫性脑炎样表现的患者,即使MRI和脑脊液无炎症,也应检测神经元表面抗体。
- 快速进展性认知衰退患者需考虑抗体相关综合征,避免误诊为神经退行性疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the CNS syndromes of patients ≥60 years of age with antibodies against neuronal surface antigens but no evidence of brain MRI and CSF inflammatory changes. METHODS: This was a retrospective clinical analysis of patients with antibodies against neuronal surface antigens who fulfilled 3 criteria: age ≥60 years, no inflammatory abnormalities in brain MRI, and no CSF pleocytosis. Antibodies were determined with reported techniques. RESULTS: Among 155 patients ≥60 years of age with neurologic syndromes related to antibodies against neuronal surface antigens, 35 (22.6%) fulfilled the indicated criteria. The median age of these 35 patients was 68 years (range 60-88 years). Clinical manifestations included faciobrachial dystonic seizures (FBDS) in 11 of 35 (31.4%) patients, all with LGI1 antibodies; a combination of gait instability, brainstem dysfunction, and sleep disorder associated with IgLON5 antibodies in 10 (28.6%); acute confusion, memory loss, and behavioral changes suggesting autoimmune encephalitis (AE) in 9 (25.7%; 2 patients with AMPAR, 2 with NMDAR, 2 with GABAbR, 2 with LGI1, and 1 with CASPR2 antibodies); and rapidly progressive cognitive deterioration in 5 (14.3%; 3 patients with IgLON5 antibodies, 1 with chorea; 1 with DPPX antibody-associated cerebellar ataxia and arm rigidity; and 1 with CASPR2 antibodies). CONCLUSIONS: In patients ≥60 years of age, the correct identification of characteristic CNS syndromes (FBDS, anti-IgLON5 syndrome, AE) should prompt antibody testing even without evidence of inflammation in MRI and CSF studies. Up to 15% of the patients developed rapidly progressive cognitive deterioration, which further complicated the differential diagnosis with a neurodegenerative disorder.
引用
- Escudero D, Guasp M, Ariño H, et al. Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology. 2017. PMID: 28878050. doi:10.1212/WNL.0000000000004541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。